Arexis’ SCCE project receives VINNOVA grant
GOTHENBURG, SWEDEN – 21 February 2005 – The Gothenburg-based drug development company Arexis AB announced today that it has received a grant totalling SEK 6.4 million from the Swedish Agency for Innovation Systems, VINNOVAThe project will evaluate the enzyme SCCE (Stratum Corneum Chymotryptic Enzyme) as target molecule for skin disorders, in order to develop new treatments for skin disease. Already, there is strong scientific evidence that SCCE plays a role in diseases such as atopic dermatitis and Netherton’s syndrome. ”The VINNOVA grant further underlines the potential in our SCCE program